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Abstract
Epithelial ovarian cancer is one of the most common gynecological
malignancies and the fifth most frequent cause of cancer death in women,
affecting over 22,000 women annually. Nearly 15,500 affected women die
from this disease annually, and chemoresistance from the commonly
prescribed platinum-based drug, carboplatin, is a major contributor to this
mortality rate. Previous studies have identified genes with CpG islands that
are methylated and transcriptionally silenced in resistant epithelial ovarian
cancer patients. One of these genes is GSK3β, an important regulator of
apoptosis and cell growth in the Wnt pathway. Thus, understanding the role
of GSK3β suppression in chemoresistance of epithelial ovarian cancer can
help contribute to more effective treatments for this disease. By performing
assays of cell growth, viability, and apoptosis, our study examined the
functional role that GSK3β plays in carboplatin mediated apoptosis. Our
results suggest that cells with suppressed GSK3β had increased proliferation
and reduced apoptosis. We conclude that silenced GSK3β expression might
therefore contribute to carboplatin resistance seen in tumors and our in vitro
analysis suggests that GSK3β expression is vital to carboplatin
chemosensitivity. Future research is required to further investigate the role of
GSK3β methylation to facilitate the design of potential genome-guided
treatments for patients with chemoresistant epithelial ovarian cancer.
Keywords: Genetics, cancer, methylation, tumor suppressor
Introduction
Oncologists are constantly seeking new, effective treatments for
epithelial ovarian cancer. The primary pharmacological treatment for this
disease is a platinum-based drug (typically carboplatin), coupled with a
taxane-based drug therapy and surgery (Lum et al., 2013; Marchini et al.,
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2012). However, 25% of these patients present with resistance to the
platinum-based drug at diagnosis, and most recurrent tumors ultimately
become resistant (Lum et al., 2013; Marchini et al., 2012). The high
prevalence of resistant epithelial ovarian tumors warrants the development of
new methods to effectively reverse chemoresistance toward carboplatin.
Previous studies have shown that several genes, including the gene GSK3β
(Glycogen synthase kinase 3 beta), undergo epigenetic changes in epithelial
ovarian cancer patients. These changes involve methylation, which causes
suppression of gene expression (Koukoura et al., 2014; Lum et al, 2013;
Arend et al., 2013). Understanding these epigenetic alterations is important
to facilitate the design of new genome-guided therapies (Tang et al., 2015;
Nestheide et al., 2013). Therefore, our study investigated the role of GSK3β
inhibition in carboplatin chemoresistance of epithelial ovarian cancer cells.

Figure 1: Heatmap of the differentially methylated genes, showing epigenetic segregation
between the platinum resistant (Res) and sensitive (Sen) patient groups. Red represents
genes that are over-expressed and blue are genes that are under-expressed. Each column
represents a patient and each row represents a gene (Lum, 2013).

Epithelial ovarian cancer is one of the most lethal gynecological
malignancies in women in the developed world, affecting over 22,000
women annually (Brain et al., 2014). Approximately 9 out of 10 ovarian
tumors are classified as epithelial (Brain et al., 2014). Chemoresistance is
among the major aforementioned challenges associated with treating this
malignancy, thereby requiring further understanding of the underlying
molecular mechanisms of this disease.
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Genetic and epigenetic alterations primarily contribute to a tumor’s
growth, and these alterations can cause resistance to chemotherapeutics
(Borley & Brown, 2015; Liu, Chan, & Ngan, 2012). Previous studies have
identified certain genes that are either under-expressed or over-expressed
differentially in chemoresistant and chemosensitive epithelial ovarian cancer
patients, as seen in Figure 1 (Borley & Brown, 2015; Earp & Cunningham,
2015; Lum et al., 2013). DNA methylation is the transfer of a methyl group
to the carbon-5 position of cytosine (Lum et al., 2013). This is an example of
an epigenetic alteration, as it regulates the temporal and spatial dynamics of
a gene and inhibits its expression (Lum et al., 2013). Recently, DNA
methylation has been shown to be involved in signaling pathways that
promote tumorigenesis in epithelial ovarian cancer (Borley & Brown, 2015;
Lum et al., 2013). Previous studies have identified CpG islands—areas
where cytosine and guanine nucleotides are adjacent to one another—in a
family of genes that are methylated and suppressed in patients with
carboplatin resistant epithelial ovarian cancer (Koukoura et al., 2014; Lum et
al., 2013). Thus, DNA methylation of genes with CpG islands in epithelial
ovarian cancer cells can be used as a therapeutic target for developing
treatments for this disease.
GSK3β, a gene involved in the regulation of Wnt signaling, cell
proliferation, and apoptosis (Figure 2), is among the identified genes that is
methylated and transcriptionally silenced in chemoresistant epithelial ovarian
cancer cells (Lum et al., 2013; Cole, 2013; Jacobs et al., 2012). This gene is
an important regulator of apoptosis, a type of genetically programmed cell
death that complements cell proliferation in normal tissues (Hilliard et al.,
2011). The response of a tumor to a chemotherapeutic agent has been shown
to be associated with its apoptotic capacity (Janzen et al., 2015; Han et al.,
2013). Thus, GSK3β may contribute to epithelial ovarian cancer cells’
response to chemotherapy. In addition, GSK3β plays a major role in the Wnt
signaling
pathway—a
signal
transduction mechanism
consisting
of transmembrane proteins that transmit signals from the extracellular matrix
into the cell (Arend et al., 2013; Barbolina, Burkhalter, & Stack, 2011). As
the Wnt pathway is involved in gene transcription, growth, and apoptosis
(Arend et al., 2013; Barbolina, Burkhalter, & Stack, 2011), its associated
genes may be implicated in the epigenetics of epithelial ovarian cancer.
The aim of our study was to investigate the effect of GSK3β
suppression (mimicking DNA methylation) on carboplatin chemoresistance
in epithelial ovarian cancer cells. We hypothesized that the inhibition of
GSK3β expression would suppress drug-induced apoptosis and promote
proliferation, thereby causing carboplatin chemoresistance. Our in vitro
findings may help elucidate the role GSK3β expression plays in
chemosensitivity and the relevance of epigenetic regulation to resistant
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epithelial ovarian cancer. Collectively, our results can be used as tools to
develop an individualized, genome-guided treatment for epithelial ovarian
cancer.

Figure 2: The pathway of GSK3β and its role in regulating cell proliferation, differentiation,
and survival (Cole, 2013).
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Cell culture and microscopic visualizations
Human ovarian surface epithelium (HOSE) 6-3 cell line was utilized,
which is characterized as sensitive to carboplatin therapy (Lum et al., 2013).
The cells were treated with either carboplatin alone (the current platinumbased drug, 200µg/mL) or LiCl (2.5mM) followed by carboplatin. LiCl acts
to suppress GSK3β gene expression (Nakada et al., 2011; Grassilli et al.,
2013). Throughout the paper, whenever suppression of GSK3β is referred to,
this indicates that the cells were pretreated with LiCl. Therefore, cells
pretreated with LiCl did not express GSK3β, whereas the cells not pretreated
expressed GSK3β. All cells were supplemented with 10-12% fetal bovine
serum, 2% penicillin-streptomycin, and grown at 37°C with 5% CO2. We
HOSE 6-3
cells were
treated
with
various
drugs,
followed
by
microscop
ic
visualizati
on to
observe
growth.
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took images of cells after two days of incubation using a fluorescence
microscope (200X), a fluorescein filter, and a fluorescent dye (Figure 3).
Neutral red dye assay
We conducted the Neutral Red Dye assay with the “In Vitro
Toxicology Assay Kit, Neutral Red Dye Based” (Sigma, Product Code
1002017798) to examine the viability of epithelial ovarian cancer cells. This
assay determines the accumulation of the red eurhodin dye (toluylene red) in
the lysosomes of viable cells, and thus more absorbance directly correlates
with more viability (In vitro toxicology assay kit neutral red based). The
cells were studied in six groups: 1) untreated; 2) treated with LiCl (to
suppress GSK3β); 3) treated with carboplatin; 4) treated with
carboplatin+LiCl; 5) treated with doxorubicin (another chemotherapeutic,
serving as a comparison); 6) treated with doxorubicin+LiCl. Cells were then
split into 96-well plates and incubated for 2 hours with Neutral Red Solution
(10 μL). Following the protocol, we removed the red dye from the wells and
washed the cells with Neutral Red Assay Fixative (100 μL). After removing
the Neutral Red Assay Fixative, we added the Neutral Red Assay
Solubilization Solution (100 μL). The 96-well plate was placed on a shaker
for ten minutes to complete dissolution. We recorded absorbance at a
wavelength of the standard 540nm using the BD Gen 5.1 microplate
colorimetric spectrometer.
Vybrant® MTT Cell Assay
We performed the Vybrant® MTT Cell Assay, using the Vybrant®
MTT Cell Assay Kit (ThermoFisher V-13154) to assess the amount of nonviable cells with the treatment groups described in the previous section. The
cleavage and conversion of the soluble yellow dye to the insoluble purple
formazan is used as a measurement of dead cells (Vybrant® MTT cell assay
kit). Following the Vybrant® MTT Cell protocol, a 12 mM MTT stock
solution [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was
prepared by adding 1 mL of sterile PBS (phosphate-buffered saline) to a 5
mg vial of MTT. The sample was vortexed until dissolved, 10 mL of 0.01 M
HCl was added to one tube containing 1 gram of SDS (sodium dodecyl
sulfate), and 10 μL of the 12 mM MTT stock solution was added to each
well. The plate was incubated at 37°C for 4 hours. The sample was read at an
absorbance of 540 nm using a spectrometer.
Caspase 3 assay
We performed the Caspase 3 assay (Abcam, ab39401) using the
Caspase 3 Assay Kit to assess the extent of apoptosis in the cells of the
aforementioned treatment groups. Following caspase cleavage, a substrate
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for luciferase (aminoluciferin) is released, resulting in a luciferase reaction
and the production of light (Caspase 3 assay kit). The absorbance of
fluorescent light as measured with the spectrometer directly corresponds to
apoptosis (Caspase 3 assay kit). The cells from each sample group were
counted using a hemocytometer and microscope; approximately 1.5 x 106
cells were aspirated. Cells were suspended in 50 μl of chilled Cell Lysis
Buffer and incubated at 5°C for ten minutes. Centrifugation at 14,000rpm
was performed for one minute. We then transferred the supernatant into a
fresh 1.5 mL tube. Following the Abcam protocol, we added 50 μl of Cell
Lysis Buffer, 2X reaction buffer, and DTT in the 1.5 mL tube.
(dithiothreitol) (10 μl). The plate was incubated for two hours. Using a
spectrophotometer, we measured absorbance at 540nm.
Cell counting
A cell suspension was prepared in a balanced salt solution (Hanks'
Balanced Salts [HBSS], Sigma-Aldrich # H9269). Samples of HOSE 6-3
cells were either: 1) untreated; 2) treated with carboplatin; 3) treated with
carboplatin+LiCl; 4) treated with doxorubicin. On the sixth day, we counted
the total number of cells in each sample per µL using a hemocytometer and a
light microscope (100X).
Data Analysis
All data represented in our study is shown as the averages with
standard deviation bars of three independent trials per experiment. T-tests
were conducted in comparison to the untreated group with Microsoft
Excel®, with p < 0.05 and p < 0.01 for significance. All experiments were
repeated three times for accuracy, in replicates of 10, unless otherwise stated.
Results
Cell Cultures and Microscopic Visualizations
The primary goal of our study was to observe how inactivation of
GSK3β contributes to carboplatin resistance in epithelial ovarian cancer
cells; thus, we qualitatively observed how GSK3β affects the cells’ response
to carboplatin. Samples of HOSE 6-3 cells were treated with carboplatin
(Figure 1A) and carboplatin+LiCl (Figure 2B), independently. Since LiCl is
known to inhibit GSK3β (Grassilli et al., 2013; Nakada et al., 2011), we
predicted that the LiCl pretreated cells would show more growth and become
resistant to carboplatin. According to Figure 3, more growth was observed
in the carboplatin+LiCl group compared to the carboplatin group alone. This
observation supports our hypothesis by suggesting that GSK3β expression in
carboplatin treated epithelial ovarian cancer cells decreased cell growth and
proliferation (Figure 3A). However, GSK3β inhibition increased cell
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growth, suggesting that the cells deficient in expressed GSK3β survived
carboplatin treatment (Figure 3B).
B

A

100 μM
Figure 3: Microscopic visualization (fluorescent microscope, magnified 200X) of HOSE 6-3
cells A) Cells treated with carboplatin exhibited less growth B) Cells treated with
carboplatin+ 2.5mM LiCl exhibited more growth

Neutral Red Dye Assay
We then proceeded to analyze the viability of HOSE 6-3 cells under
various treatments with active and silenced GSK3β in order to determine the
level of chemoresistance through the Neutral Red Dye assay (Figure 4).
Increased absorption of the red dye indicates increased cell viability. HOSE
6-3 cells pretreated with LiCl were exposed to carboplatin as the main
treatment and doxorubicin as an independent control. Another group of cells
(LiCl untreated) were exposed to carboplatin and doxorubicin (Figure 4).
Since LiCl inhibits GSK3β, we predicted that the LiCl pretreated cells would
become resistant to carboplatin (Figure 4). Among the LiCl untreated cells,
those exposed to carboplatin were less viable (absorbance level:
0.38nm±0.13nm SD, 540nm, p-value: 1.94 x 10-19) compared to those left
untreated (absorbance level: 1.21nm±0.12nm SD, 540nm). However, among
the cells pretreated with LiCl, the ones treated with carboplatin showed
similar levels of viability (absorbance level: 1.19nm±0.094nm SD, 540nm,
p-value: 1.25 x 10-19) as the untreated ones. Viability of cells treated with
doxorubicin remained independent of GSK3β expression. We repeated this
process in three independent trials, each consisting of 10 replicates (Figure
4). Each of the three independent trials consistently showed that cells
expressing GSK3β with carboplatin treatment were less viable (Figure 4).
However, the cells with suppressed GSK3β were more viable upon
carboplatin administration, absorbance measured at 540-nm (Figure 4).
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Figure 4: GSK3β determines chemoresistance as a function of viability. Cells treated with
carboplatin and doxorubicin had lower viability than cells treated with carboplatin+LiCl.
(Carbo=Carboplatin, Doxo=Doxorubicin). The results represent the mean±SD (n=3) (*
denotes p <0.05, ** denotes p <0.01)

Vybrant® MTT Cell Assay
To further assess the validity of our hypothesis, we determined
whether active GSK3β affects chemoresistance to carboplatin or doxorubicin
through the Vybrant® MTT Cell assay. This biochemical assay uses
fluorescent indicators indicates greater levels of non-viable cells. Samples of
HOSE 6-3 cells were untreated, treated with LiCl alone, carboplatin,
carboplatin+LiCl, doxorubicin (comparison), or doxorubicin+LiCl (Figure
5). We predicted that the cells with GSK3β suppressed would show greater
cell viability compared to the cells with the active form of GSK3β.
According to Figure 5, the cells treated with carboplatin and doxorubicin
(separately) showed the highest absorbance (1.42nm±0.23nm SD and
1.77nm±0.35nm SD respectively, p-values: 3.9 x 10-6 and 1.9 x 10-9),
thereby indicating the greatest amounts of non-viable cells. In contrast, the
cells treated with carboplatin+LiCl had similar amounts of cell viability
(absorbance level: 0.49nm±0.05nm SD, p-values: 3.2 x 10-5) as the untreated
groups (absorbance level: 0.48nm±0.13nm SD). Each of the three
independent trials consistently showed that cells expressing GSK3β with
carboplatin treatment were not viable. However, cells with suppressed
GSK3β were viable upon carboplatin administration (Figure 5).
Additionally, cells treated with doxorubicin+LiCl had a similar absorbance
(1.52nm±0.13nm SD, p-value: 3.4 x 10-2) as doxorubicin alone
(1.71nm±0.23nm SD, p-value: 1.9 x 10-9) (Figure 5, 540nm absorbance).
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Figure 5: GSK3β determines chemoresistance as a function of non-viability. The sample
treated with carboplatin had many non-viable cells. Cells treated with carboplatin and LiCl
had a lower amount of non-viable cells, almost identical to that of the untreated cells.
(Carbo=Carboplatin, Doxo=Doxorubicin). The results represent the mean±SD, n=3. (*
denotes p <.05, ** denotes p <.01)

Caspase 3 Assay
GSK3β plays a pivotal role in regulating apoptosis, and since a
tumor’s response to chemotherapy has been shown to be correlated with
apoptotic-induction (Janzen et al., 2015; Han et al., 2013) we sought to
analyze apoptosis in cell samples with or without expressed GSK3β. To
achieve this, we performed the Caspase 3 assay. Treatments mirrored the
groups in the previous protocols (Figure 4 and 5). Figure 6 illustrates that
the cells treated with carboplatin+LiCl were less apoptotic, compared to cells
with carboplatin alone. In other words, cells expressing GSK3β were more
susceptible to carboplatin, thus showing increased apoptosis (absorbance
levels: 0.69nm±0.12nm SD, p-values-7.0 x 10-8). This is in direct contrast to
cells that did not express GSK3β and were exposed to carboplatin
(absorbance level: 0.16nm±0.002nm SD, p-value: 1.9 x 10-2). Figure 6
shows that GSK3β suppression did not affect the extent of apoptosis under
doxorubicin treatment but did affect apoptosis under carboplatin treatment.
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Figure 6: GSK3β determines chemoresistance as a function of apoptosis. Cells treatment
with carboplatin had much higher levels of apoptosis than untreated. The cells with
carboplatin and LiCl had very low levels of apoptosis, almost identical to those of the
untreated cells. (Carbo=Carboplatin, Doxo=Doxorubicin). The results represent the
mean±SD, n=3. 5 (* denotes p <0.05, ** denotes p <0.01)

Cell Counting
To
quantify cell growth and proliferation of the cells with expressed
*
and suppressed GSK3β, we performed cell counts on samples of HOSE 6-3
cells (Figure 7). We had a sample of HOSE 6-3 cells, which were untreated,
and another sample that was treated with carboplatin, carboplatin+LiCl, and
doxorubicin (independently); these samples were incubated and counted after
two days using a hemocytometer and a light microscope (100X). Figure 7
highlights how there was less growth with doxorubicin. Additionally, cells
treated with carboplatin+LiCl had similar amounts of growth (1.18 x 106
cells/µL, p-value: 7.63 x 10-3) as the untreated cells. All results reflect three
independent trials with 10 replicates each. However, cells with carboplatin
alone had significantly less growth (6.2 x 105 cells/µL, p-value: 2.93 x 10-2).
Thus, GSK3β suppression causes more growth following carboplatin
exposure.
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Figure 7: GSK3β determines chemoresistance as a function of cell number. Cell Counting
using a light microscope (100X): Cells with carboplatin+LiCl grew and proliferated at
almost the same rate as the untreated cells. Cells with carboplatin and doxorubicin grew at a
much slower rate. Results represent the mean±SD (n=3). (* denotes p <0.05, ** denotes p
<0.01 compared to untreated)

Conclusion and Discussion
Chemoresistance in epithelial ovarian cancer is an important clinical
issue as it presents a major limitation to effective treatment and addressing
recurrence. Previously, it has been shown that gene expression differs
between chemoresistant and chemosensitive epithelial ovarian cancer
patients (Figure 1) (Borley & Brown, 2015; Lum et al., 2013; Cole, 2013).
The mechanisms responsible for a tumor’s ability to resist treatment are
often caused by epigenetic alterations, including gene methylation (Liu,
Chan, & Ngan, 2012). We investigated GSK3β expression to identify
potential gene targets for carboplatin resistant epithelial ovarian cancer.
GSK3β is a major regulator of cell apoptosis and growth in the Wnt pathway
(Lum et al., 2013; Jacobs et al., 2012). This gene has been shown to be
methylated and suppressed in epithelial ovarian cancer and has been
implicated in chemoresistance of other cancers (Grassilli et al., 2013; Lum et
al., 2013; Jacobs et al., 2012). Thus, we examined the role of GSK3β in
epithelial ovarian cancer cells that were known to be carboplatin sensitive as
described by our previous publication (Lum et al., 2013). In our study, we
assessed cell viability, apoptosis and growth (Figures 3 to 7) in the HOSE 63 cell line, pretreated with LiCl (GSK3β suppressed) or without LiCl
(GSK3β expressed). LiCl inhibits GSK3β expression through two
mechanisms: 1) Promoting Ser-9 phosphorylation, an inhibitory marker, and
2) Blocking Mg2+ ions from binding, thus preventing activation of GSK3β
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(Grassilli et al., 2013; Nakada et al., 2011). In the future we plan to further
elucidate the mechanisms involved in the signal transduction pathway of
GSK3β in our cell lines.
Microscopically visualizing cells under different treatments was
necessary in studying the role of GSK3β inhibition in cell growth and
carboplatin chemoresistance (Figure 3). There were fewer viable cells after
carboplatin exposure in cells without 2.5mM LiCl treatment compared to
cells with LiCl treatment; this suggests the role of GSK3β expression in cell
protection and apoptosis (Figure 3). Results from the Neutral Red Dye
assay, Vybrant® MTT Cell assay, Caspase 3 assay, and direct cell counts
assays provided further support for our hypothesis (Figure 4 to 6).
Analyzing viability of the cells under different treatments was critical
to studying the role of GSK3β inhibition in chemoresistance. We determined
overall cell viability with the Neutral Red Dye and Vybrant® MTT Cell
assays. According to the Neutral Red Dye assay, carboplatin treatment
significantly decreased cell viability in cells that expressed GSK3β (p-value:
1.94 x 10-19) (Figure 4). However, in cells with silenced GSK3β, carboplatin
was not effective in decreasing viability (p-value: 1.25 x 10-19) (Figure 4).
This suggests that GSK3β is critical to cellular viability, and suppressing its
expression may result in chemoresistance. Sensitivity to doxorubicin
remained independent of GSK3β expression, suggesting that GSK3β
inhibition affects carboplatin resistance, but not doxorubicin resistance. This
is perhaps because doxorubicin has a different mechanism of action that may
be GSK3β independent (Thorn et al., 2012). Future work in our lab
continues to examine the variable mechanisms of action of both drugs.
Next, the Vybrant® MTT Cell assay analyzed cell viability with
active and silenced GSK3β, treated with carboplatin and doxorubicin,
independently (Figure 5). Our results show that the untreated cells had
almost identical amounts of non-viable cells as those treated with
carboplatin+LiCl (p-value: 3.2 x 10-5); this once again suggests that
suppressing GSK3β can potentially lead to carboplatin chemoresistance
(Figure 5), as it resulted in a direct effect on cellular viability. However, the
HOSE 6-3 cells with expressed GSK3β were significantly less viable upon
carboplatin exposure, suggesting that the cells were selectively transformed
upon the addition of LiCl and remained chemosensitive (p-value: 3.9 x 10-6)
(Figure 5). Additionally, the sample treated with doxorubicin and
doxorubicin+LiCl independently had similar amounts of non-viable cells,
suggesting that GSK3β suppression does not affect resistance to doxorubicin.
Future studies are required to elucidate how the suppression of GSK3β
results in carboplatin resistance, and how the expression of GSK3β results in
carboplatin sensitivity by looking at upstream and downstream targets in the

126

European Scientific Journal May 2016 edition vol.12, No.15 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431

Wnt/ β-catenin pathway. Current research in our lab suggests that GSK3β
acts independently in this role (results not shown).
One major path of chemoresistance involves the dysregulation of
apoptosis. Dysfunctional apoptotic responses may result in uncontrolled cell
growth, leading to cancer (Han et al., 2013). The efficacy of most
chemotherapeutics, such as platinum-based drugs, relies heavily on their
ability to induce apoptosis (Lum et al., 2013). As a consequence,
chemoresistant cells often have down-regulated pro-apoptotic genes or upregulated anti-apoptotic genes (Lum et al., 2013). To determine whether
GSK3β expression specifically affects apoptosis, the Caspase 3 assay was
performed (Figure 6). Since GSK3β is involved in regulating apoptosis
(Lum et al., 2013; Jacobs et al., 2012), we analyzed apoptosis levels in cells
with various treatments, with or without GSK3β (Figure 6). Carboplatin
induced a significantly greater level of apoptosis in this cell line (p-value: 7.0
x 10-8) when compared to untreated cells (Figure 6). These results suggest
that the cells with active GSK3β continue to undergo apoptosis when treated
with carboplatin. In contrast, cells treated with carboplatin+LiCl (p-value:
1.9 x 10-2), showed no difference in levels of apoptosis compared to
untreated cells (Figure 6), strongly suggesting that GSK3β suppression plays
a critical role in modification of carboplatin apoptotic pathways. When
GSK3β was inhibited in cells treated with doxorubicin (p-value: 4.1 x 10-7),
the sample showed nearly identical levels apoptosis as the sample with
GSK3β expressed (p-value: 7.6 x 10-5); this finding suggests that GSK3β
affects carboplatin apoptotic pathways selectively; this may be because of
the fact that carboplatin and doxorubicin belong to different classes of drugs;
carboplatin is classified as an alkylating agent, whereas doxorubicin is an
anthracycline antibiotic (Thorn et al., 2012). Thus, GSK3β may regulate
carboplatin chemosensitivity because it is associated with the same apoptotic
pathway that carboplatin induces. Doxorubicin has a different mechanism of
action that we predict is GSK3β independent (Thorn et al., 2012). Figure 6
highlights the expression of GSK3β as a determinant for carboplatin-induced
apoptosis among HOSE 6-3 cells. These results demonstrate that the
inhibition of GSK3β reduces carboplatin-induced apoptosis, which may be
responsible for chemoresistance as observed in clinical cases (Conic et al.,
2015; Lum et al., 2013). We have seen the same modification of apoptosis
in our lab using cisplatin, another alkylating agent with similar properties to
carboplatin, suggesting GSK3β plays a selective role in platinum based
apoptotic pathway signaling (results not shown). Platinum based drugs have
the ability to add alkyl groups to many electronegative groups, thereby crosslinking strands of DNA (Sharon et al., 2009).
Cell growth was assessed directly through cell count (Figure 7).
There was significantly less cell growth with doxorubicin (p-value: 3.89 x
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10-2). There was less cell growth with carboplatin as well (p-value: 2.93 x 102
). However, there was significantly more cell growth when the sample was
pretreated with LiCl followed by carboplatin (p-value: 7.63 x 10-3) (Figure
7). Collectively, our results support our other studies (Lum et al., 2013) and
demonstrate that suppression of GSK3β leads to modification of cellular
viability by increasing cellular growth when GSK3β is silenced.
Importantly, our results suggest that this change in cellular viability can
result in chemoresistance, and expression of GSK3β leads to carboplatin
chemosensitivity.
Epithelial ovarian cancer is one of the deadliest gynecological
malignancies that affects women worldwide (Liu, Chan, & Ngan, 2013).
Evidence from previous studies shows that genetic and epigenetic alterations
are major underlying mechanisms that contribute to tumorigenesis,
especially in epithelial ovarian cancer (Borley & Brown, 2015; Liu, Chan, &
Ngan, 2013). Chemoresistance to the current platinum-based therapy in such
cases is a major obstacle for the clinical management of epithelial ovarian
cancer (Borley & Brown, 2015; Liu, Chan, & Ngan, 2012). Thus, developing
a treatment that prevents or reverses chemoresistance is vital for the survival
of epithelial ovarian cancer patients. To overcome this challenge, it is
important to study genes involved in epithelial ovarian cancer. Recent
studies have identified genes with CpG islands that undergo epigenetic
alterations, particularly methylation, and are associated with the acquisition
of chemoresistance in epithelial ovarian cancer (Koukoura et al., 2014; Lum
et al., 2013; Zeller et al., 2011). Specifically, GSK3β is a gene with CpG
islands that has been shown to be transcriptionally silenced via methylation
in resistant epithelial ovarian cancer patients (Lum et al., 2013; Jacobs et al.,
2012). Therefore, our study focused on GSK3β and its relation to carboplatin
chemoresistance in epithelial ovarian cancer. By performing various assays
of cell growth, viability, and apoptosis, our study successfully supported our
hypothesis by demonstrating that GSK3β suppression results in tumorigenic
properties and carboplatin chemoresistance (Figures 3 to 7). These results
strongly suggest that GSK3β expression plays a significant (p < 0.05 or p <
0.01) role in carboplatin sensitivity, supporting previous studies that have
been done involving other genes with chemoresistant epithelial ovarian
cancer (Lum et al., 2013). In the future, therapies can be developed that
target GSK3β and the Wnt pathway. These findings hold promise for future
genome-guided chemotherapy based on a patient’s individual gene
expression profile (Tang et al., 2015; Nestheide et al., 2013).
Another approach we propose is to target other downstream effectors
of GSK3β in the Wnt signaling pathway, such as β-catenin (Figure 2).
Currently this is an active area of research in our lab. Additionally, our
recent research suggests that blocking methylation with a demethylating
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enzyme can reverse carboplatin chemoresistance (Cheishvili et al., 2015).
However, it is difficult to solely block methylation of a single gene in vivo
without disrupting other normal epigenetic processes (Handy, Castro, &
Loscalzo, 2012). Hence, we can use our data and explore the Wnt/β-catenin
pathway to create a more targeted treatment. Figure 2 suggests that
inhibiting this gene via methylation would inhibit downstream effectors of
GSK3β, such as β-catenin, resulting in uncontrolled proliferation and
tumorigenic properties (Arend et al., 2013; Cole, 2013). Thus, we suggest
that activating these downstream effectors, such as β-catenin, would be
effective in circumventing this process and blocking proliferation signaling.
Additional studies in upregulating β-catenin are necessary to examine the
efficacy of this approach. We plan to actively research this in the future.
Our study demonstrates that the inhibition of GSK3β plays a major
role in carboplatin chemoresistance of epithelial ovarian cancer, and its gene
expression promotes carboplatin sensitivity. Studying the role of epigenetics
and methylated genes, such as GSK3β, in chemoresistance of epithelial
ovarian cancer can lead to increased accuracy in diagnosis, prognosis, and
treatment of this disease. All the above-stated investigations could improve
treatment efficacy, reduce the need for more aggressive treatment modalities,
and facilitate the development of specific genome-guided therapy that target
resistant epithelial ovarian tumors.
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